PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9334201-2	1997	Mice homozygous for a deletion in the gene for CEBPalpha (C/EBPalpha-/- mice) die shortly after birth of hypoglycemia, with no detectable hepatic PEPCK mRNA and negligible hepatic glycogen stores.	Glycogen	180-188	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	47-56	
9334201-3	1997	Half of the mice homozygous for a deletion in the gene for CEBPbeta (C/EBPbeta-/- mice) have normal glucose homeostasis (phenotype A), and the other half die at birth of hypoglycemia due to a failure to express the gene for PEPCK and to mobilize hepatic glycogen (phenotype B).	Glycogen	254-262	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	59-67	
9334201-4	1997	Insulin deficiency induces C/EBPalpha and PEPCK gene transcription in the livers of 19-day fetal rats, whereas dibutyryl cyclic AMP (Bt2cAMP) increases the expression of the gene for C/EBPbeta and causes a transient burst of PEPCK mRNA.	Bucladesine	111-131	CCAAT/enhancer binding protein beta	Rattus norvegicus	183-192	
9334201-4	1997	Insulin deficiency induces C/EBPalpha and PEPCK gene transcription in the livers of 19-day fetal rats, whereas dibutyryl cyclic AMP (Bt2cAMP) increases the expression of the gene for C/EBPbeta and causes a transient burst of PEPCK mRNA.	Bucladesine	111-131	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	225-230	
9334201-5	1997	Bt2cAMP induces PEPCK mRNA in the livers of fetal C/EBPalpha-/- mice, but at only 20% of the level of control animals; however, there is no induction of PEPCK mRNA if the cyclic nucleotide is injected into C/EBPalpha-/- mice immediately after delivery.	Bucladesine	0-7	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	16-21	
9334201-5	1997	Bt2cAMP induces PEPCK mRNA in the livers of fetal C/EBPalpha-/- mice, but at only 20% of the level of control animals; however, there is no induction of PEPCK mRNA if the cyclic nucleotide is injected into C/EBPalpha-/- mice immediately after delivery.	Bucladesine	0-7	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	50-60	
9334201-5	1997	Bt2cAMP induces PEPCK mRNA in the livers of fetal C/EBPalpha-/- mice, but at only 20% of the level of control animals; however, there is no induction of PEPCK mRNA if the cyclic nucleotide is injected into C/EBPalpha-/- mice immediately after delivery.	Bucladesine	0-7	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	50-63	
9334201-6	1997	The expression of the gene for C/EBPbeta is markedly induced in the livers of C/EBPalpha-/- mice within 2 h after the administration of Bt2cAMP.	Bucladesine	136-143	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	31-40	
9334201-6	1997	The expression of the gene for C/EBPbeta is markedly induced in the livers of C/EBPalpha-/- mice within 2 h after the administration of Bt2cAMP.	Bucladesine	136-143	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	78-91	
9334201-8	1997	In C/EBPbeta-/- mice with phenotype B, the administration of Bt2cAMP immediately after delivery induces PEPCK mRNA, causes the mobilization of hepatic glycogen, and maintains normal glucose homeostasis for up to 4 h (duration of the experiment).	Glycogen	151-159	belted 2	Mus musculus	61-64	
9334201-9	1997	We conclude that C/EBPalpha is required for the cAMP induction of PEPCK gene expression in the liver and that C/EBPbeta can compensate for the loss of C/EBPalpha if its concentration is induced to appropriate levels.	Cyclic AMP	48-52	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	17-27	
9334201-9	1997	We conclude that C/EBPalpha is required for the cAMP induction of PEPCK gene expression in the liver and that C/EBPbeta can compensate for the loss of C/EBPalpha if its concentration is induced to appropriate levels.	Cyclic AMP	48-52	phosphoenolpyruvate carboxykinase 1, cytosolic	Mus musculus	66-71